← SynDRA
ORLISTAT
SynDRA canonical compound SYN0005491 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | LIPF |
|---|
| Mechanism of action | Lipase inhibitor |
|---|
| Indication | weight-loss aid |
|---|
| Disease area | endocrinology |
|---|
All known targets
- PNLIP
- LIPF
- CNR1
- DAGLA
- FASN
- DAGLB
- ABHD12
- ABHD16A
- ABHD6
- Dagla
- Faah
- LIPC
Mechanisms of action (all sources)
- Lipase inhibitor
- LIPF INHIBITOR
- Gastric lipase inhibitor
- PNLIP INHIBITOR
- Pancreatic lipase inhibitor
- CNR1 INHIBITOR
- PNLIP MODULATOR
Drug classes
- Lipase Inhibitors
- Intestinal Lipase Inhibitor
- Anti-Obesity Agents
- Enzyme Inhibitors
- Lipid Regulating Agents
ATC classes
- A08A · ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Cross-references
Synonyms
- tetrahydrolipstatin
- xenical
- alli
- tetrahydrolipastatin
- Lipstatin
- Orlipastat
- Tetrahydrolipstatin
- NSC-758881
- RO-18-0647/002
- RO-180647-002
- RO-180647002
- Ro-18-0647-002
- Alli
- Alli (previously orlistat gsk)
- Beacita
- Xenical
- (-)-Tetrahydrolipstatin
- Orlipastatum
- Orlipastatum [INN-Latin]
- THLP
- Ro-18-0647
- UNII-95M8R751W8
- C29H53NO5
- Ro 18-0647/002
- N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
- (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate
- Orlistat (Alli, Xenical)
- MLS002207022
- [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
- CHEMBL175247
- GlaxoSmithKline brand of orlistat
- Roche brand of orlistat
- Alli (TN)
- Hoffmann-La Roche brand of orlistat
- KS-1183
- Orlistat [USAN:INN]
- R-212
- Xenical (TN)
Look up ORLISTAT in the interactive SynDRA portal →